All In Biotech

NDA 216632 · Bausch

Cabtreo

Adapalene, Benzoyl Peroxide, Clindamycin Phosphate · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: Oct 20, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 20, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

112

28 Phase 3, 7 recruiting

FAERS reports

60

8 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2025.

CABTREO is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older. CABTREO is a combination of clindamycin phosphate (a lincosamide antibacterial), adapalene (a retinoid), and benzoyl peroxide indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older. ( 1 )

Mechanism: Clindamycin: Clindamycin is a lincosamide antibacterial [see Microbiology ( 12.4 )] . Adapalene: Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CABTREO · ADAPALENE 0.15%; BENZOYL PEROXIDE 3.1%; CLINDAMYCIN PHOSPHATE 1.2% · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Adapalene" as an intervention, any sponsor and status, largest first.

All 112 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site pain7
  • drug hypersensitivity6
  • application site dryness5
  • drug ineffective5
  • application site pruritus4
  • application site erythema3
  • erythema3
  • hypersensitivity3
  • pain3
  • product use issue3
  • pruritus3
  • accidental exposure to product2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202414
202531
202615

Recalls

1 FDA enforcement reports for this application.

  • Feb 12, 2024 · Class II · Terminated

    CGMP Deviations: Product was stored outside labeled storage temperature requirements. Product was exposed to controlled room temperature environment instead of remaining refrigerated.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cabtreo (Adapalene/Benzoyl/Clindamycin)

2024 spending

$197K

Beneficiaries

125

210 claims

Per beneficiary

$1,572

$18.13 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$196,507

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 219 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.